http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20040031405-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5e84c934b1d2a75f9de9c4db1897a9dd |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-12 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1131 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 |
| filingDate | 2002-10-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4612ffe8bd79f48a5f1d50eeae98a953 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d1d6dc01597b611d7a74f8f671e97b60 |
| publicationDate | 2004-04-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20040031405-A |
| titleOfInvention | Trans-Splicing Ribozyme Mediated Selective Induction of Gene Activity in Hepatitis C Virus Internal Ribosome Entry Site-Expressing Cells |
| abstract | The present invention relates to trans-splicing ribozymes that selectively induce specific gene activity by targeted trans-splicing reactions only in IRES (Internal Ribosome Entry Site) expressing cells of hepatitis C virus. The trans-splicing ribozyme of the present invention is a modification of the trans-splicing group I ribozyme, wherein a gene that is expressed in HCV IRES expressing cells at the 3 'exon region of the ribozyme and inhibits the proliferation of HCV The gene is inserted in the 3 'region after the site cut out from the HCV IRES by the trans-splicing reaction of the HCV IRES by the ribozyme before the HCV proliferation-related gene It includes. Therefore, when injected into the HCV IRES-expressing cell and trans-splicing the HCV IRES, the specific region of the HCV IRES is recognized to inhibit the expression of a gene necessary for survival of the HCV or to express the HCV proliferation-associated gene. Induce. According to the trans-splicing ribozyme of the present invention, since HCV can not only destroy HCV RNA in infected cells but also produce antiviral protein, it can provide a therapeutic agent that can inhibit the growth of HCV more effectively. It is expected to be able. |
| priorityDate | 2002-10-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 69.